Navigation Links
3SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2008 Results
Date:3/11/2009

ubmit application for clinical trials of NuPIAO, the Company's second generation EPO product. -- Leverage Nephrology and Oncology focused franchise and strong balance sheet to continue efforts in the business development front. -- Complete construction on our new EPIAO plant to support future growth of EPIAO in China, and as the first step towards exploring global biosimilar opportunities.

Based on these goals and current market and operating conditions, the Company's total net revenue target for the full year 2009 is estimated to be between US$43 million to US$45 million, resulting in year-over-year increase of approximately 21% to 26%.

Conference Call

3SBio's senior management will host a conference call at 5:00 am (Pacific) / 8:00 am (Eastern) / 8:00 pm (Beijing/Hong Kong) on Thursday, March 12, 2009. The conference call may be accessed using the dial-in numbers below:

    International Toll Dial-In Number:    +6567357955
    China  (Landline)                     800 819 0121
    China (Mobile)                        400 620 8038
    U.K.                                  08082346646
    U.S.                                  18665194004
    H.K.                                  800933053
    Conference ID:                        87494181

A telephone replay will be available shortly after the call until March 19, 2009, at:

    International Dial-In Number:         +61 2 8235 5000
    U.S. Dial-in Number:                  18662145335
    Conference ID:                        87494181

A live webcast of the conference call and the replay will be available on the investor relations page of 3SBio's website at http://www.3sbio.com/en/News/ShowInfo_nnn11.aspx?ID=71 .

Reconciliation of GAAP to Adjusted Non-
'/>"/>

SOURCE 3SBio Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Related biology technology :

1. 3SBio Inc. Receives Official Recognition as a High-Tech Enterprise
2. 3SBio Inc. to Report 2008 Fourth Quarter and Full Year Earnings on March 11, 2009
3. 3SBio Inc. Appoints Mr. Bo Tan as Chief Financial Officer
4. 3SBio Inc. to Present at the Piper Jaffray 20th Annual Health Care Conference
5. 3SBio Inc. Announces Third Quarter 2008 Results
6. 3SBio Inc. Files for SFDA Approval of NuLeusin
7. 3SBio Inc. Announces Preliminary Third Quarter 2008 Results
8. 3SBio Inc. Schedules 2008 Third Quarter Earnings Release on Monday, November 10, 2008
9. 3SBio Inc. Files for SFDA Approval of High-dose (36,000 IU) EPIAO
10. 3SBio Inc. to Present at the UBS Global Life Sciences Conference
11. 3SBio Inc. Announces Results of Annual General Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)... 600 medical research executives, scientists, policy makers, and funders ... funding strategies at the inaugural Partnering for Cures ... center of the Milken Institute, convened Partnering for ... a scientific discovery into an accessible therapy. This ...
(Date:12/2/2009)... CALGARY, Dec. 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics" ... that in connection with its previously announced unit offering, ... and purchased an additional 637,500 units. Each unit is ... common share purchase warrant, and was sold at a ...
(Date:12/2/2009)... Mass., Dec. 2 TechConnect World, an event ... product integration in cleantech, nanotech, biotech and MEMS, ... and business presentations. ,, Now in its 14th ... Science and Technology Institute (NSTI), and the Clean ...
(Date:12/2/2009)... Dec. 2 /PRNewswire-Asia-FirstCall/ -- Emerald Dairy, Inc.,("Emerald Dairy" or ... distributor of infant and children,s formula, milk powder and,soybean ... be featured,in the Spring issue of US Food & ... 250,000 executives in the food and beverage industry. , ...
Breaking Biology Technology:Medical Research Leaders Explore Novel Strategies to Expedite the Search for Cures 2Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 2Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 3Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 4Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 3Emerald Dairy To Be Featured in Spring Issue of US Food and Drink Executive 2
... Wis. - Quintessence Biosciences , a biopharmaceutical ... of its EVade cancer treatments, has been selected for ... said that pending a favorable preclinical safety assessment, it ... Administration an investigational new drug application in late ...
... the word sustainability in a crowd of business executives ... you as an aging hippie, then scrambled away to ... , ,Today, sustainability still carries some linguistic baggage, but ... because there's no avoiding a rational conversation. Global climate ...
... - Every week, we read high-profile stories about ... a laptop computer or computer network. This sensitive information ... and the government, with little accountability for such security ... knights in shining armor, the Wisconsin Legislature ...
Other Biology Technology:Re-engineering our economy to be sustainable and profitable 2Re-engineering our economy to be sustainable and profitable 3Re-engineering our economy to be sustainable and profitable 4Wisconsin identity theft law: A cheap plastic sword 2Wisconsin identity theft law: A cheap plastic sword 3
(Date:12/3/2009)... undergo a personality change in warmer water, according to an ... species more aggressive. , Experiments with two species of young ... first time that some reef fish are either consistently timid, ... more marked as water temperatures rise. , A slight lift ...
(Date:12/3/2009)... comes to investment in energy efficient technologies research, but ... Dave Delpy believes that more is needed: "Scientific and ... wind and solar power solutions, but more investment is ... we are to meet our carbon emission targets by ...
(Date:12/2/2009)... PHILADELPHIA Less acculturated Latino men have a more ... acculturated to U.S. culture, but acculturation has no affect ... findings are published in Cancer Epidemiology, Biomarkers & ... Cancer Research. The December issue has a special focus ...
Breaking Biology News(10 mins):Fish with attitude: Some like it hot 2Research is vital to a cleaner, greener, low carbon future 2Acculturation affects smoking cessation success among Latinos 2Animes fan girls 49360 1Animes fan girls 49360 2Stroke survivors report loss of sexual desire blurred gender roles anger and fatigue 49357 1Stroke survivors report loss of sexual desire blurred gender roles anger and fatigue 49357 2Stroke survivors report loss of sexual desire blurred gender roles anger and fatigue 49357 3Stroke survivors report loss of sexual desire blurred gender roles anger and fatigue 49357 4Wound Care Certification Program Gives Healthcare Sales Professionals Competitive Edge in Tough Economy 49355 1
... Tomorrow, PETA will donate $120,000 to the Duluth-based ... its important work aimed at improving toxicity testing and ... routinely maimed and killed in laboratory experiments. PETA will ... 25, at the Inn on Lake Superior in Duluth. ...
... to have a profound impact on human physiology as ... new study led by researchers from the Biodesign Institute ... passengers flown in spacemicrobescan be equally affected by space ... alters cellular and physiological responses in astronauts including the ...
... Hamilton, ON. Sept. 24, 2007 Men who have ... high-pitched voices, researchers have found. And their study ... with low-pitched voices. , The study, published in Biology ... voice as well as how we choose our mates. ...
Other Biology News:PETA awards $120,000 to Duluth Foundation for advancing non-animal tests 2Spaceflight shown to alter ability of bacteria to cause disease 2Spaceflight shown to alter ability of bacteria to cause disease 3Spaceflight shown to alter ability of bacteria to cause disease 4
HybriWell™ hybridization sealing system, 20 mm diameter chamber, 0.15 mm deep *set of 100*...
Recombinant Equine TNF-alpha/TNFSF1A, CF...
GRADIENT MAKER, 30 ML, 1 EA. Category: Protein Vertical Instruments....
DALT GRADIENT MAKER,230V, 1 EA. Category: 2D DALT Systems....
Biology Products: